Newsroom
Latest News
News
Sera Presents Data Demonstrating Prediction of Preeclampsia Utilizing Protein Biomarker and Clinical Factors at SRI Annual Meeting
Salt Lake City, March 18, 2022 —Sera Inc., The PregnancyCompany ® (Nasdaq: SERA), focused on improving maternal and neonatal healthby providing innovative pregnancy biomarker information to doctors and patients,today presented data…
News
Sera To Present At Upcoming March Investor Conferences
Salt Lake City – March 3, 2022 – Sera Inc., The PregnancyCompany ® (Nasdaq: SERA), focused on improving maternal and neonatal healthby providing innovative pregnancy biomarker information to doctors and patients,today announced that…
News
Sera Presentation Rescheduled For Citi 2022 Healthcare Conference
Salt Lake City – February 17, 2022 – Sera Inc., The PregnancyCompany ® (Nasdaq: SERA), focused on improving maternal and neonatal healthby providing innovative pregnancy biomarker information to doctors and patients,today announced that…
News
Sera To Present At Upcoming February Investor Conferences
Salt Lake City – February 7, 2022 – Sera Inc., The PregnancyCompany ® (Nasdaq: SERA), focused on improving maternal and neonatal healthby providing innovative pregnancy biomarker information to doctors and patients,today announced that…
News
Sera Announces New Agreement With Multiplan, Expanding Patient Access To The PreTRM® Test
Feb 1, 2022, Sera announced the execution of an agreement with MultiPlan, for participation in its PHCS and MultiPlan Networks.
News
Sera Added To Nasdaq Biotechnology Index
Dec 15, Sera announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI).
News
Sera Announces Pricing For PreTRM® Test, The Only Broadly Validated Blood Test To Assess Risk Of Preterm Birth
Dec. 2, 2021, Sera announced the Centers for Medicare & Medicaid Services (CMS) has set a Medicare payment rate for the existing unique Proprietary Laboratory Analysis (PLA) code, 0247U, for the PreTRM® Test.
News
Sera Announces Publication Of Data Confirming The Performance Of The Ibp4/shbg Biomarkers In Diverse Non-u.s. Populations
Dec. 1, 2021, The newly published article presents the performance of the IBP4/SHBG biomarker pair in predicting spontaneous preterm birth (sPTB) in low and middle income geographies, with prespecified adjustment for demographic differences between the populations.
News
Sera Announces The Appointment Of Sandra A. J. Lawrence To The Sera Board
Nov. 30, 2021, Sera announced that Sandra A. J. Lawrence has joined the Sera Board of Directors.
News
Sera Announces The Appointment Of Zhenya Lindgardt To Its Board Of Directors
Nov 8,2021, Sera announced that Zhenya Lindgardt has joined the Sera Board of Directors.